£1M+ Innovate UK grant will fund the first real-world test of a distributed hub-and-spoke manufacturing network across three sites making the same therapy under centralized quality control
LONDON, UK, November 19, 2026 – Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced that it is leading a consortium awarded £1,055,756 by Innovate UK as part of the Transforming Medicines Manufacturing Innovation programme. The funding will support a proof-of-concept pilot of decentralized cell therapy manufacturing. The consortium includes Adthera Bio and the Cell and Gene Therapy Catapult (Catapult) with Seal serving as the Manufacturing Execution System (MES) service provider.
The pilot will test a decentralized hub-and-spoke model built around Ori’s IRO® automated, digital manufacturing platform. In this model, hospitals, CDMOs and CGT manufacturers form a network of qualified manufacturing sites—the spokes. Under the UK regulatory framework, the hub acts as the licensed Control Site, holding the manufacturing licence and overseeing GMP compliance, quality management and batch certification and release across the network.
The pilot will test whether IRO automation and digital tools, when combined with Seal’s MES/eBMR system, can make this approach work in practice, with the aim of delivering cell therapies more quickly and cost-effectively than traditional centralized manufacturing.
What the pilot will do
Between November 2026 and January 2028, the consortium will:
- Tech transfer to three sites. The same cell therapy will be produced on the automated IRO platform at three UK sites: at Ori’s labs in London, at Adthera Bio in Birmingham and at CGT Catapult’s Development and Analytical Testing (DAT) laboratories in Stevenage using consistent starting materials to show equivalence across sites.
- Demonstrate multi-site comparability. Products from all three sites will be tested against the same pre-specified criteria to show that the product can be made to consistent quality in multiple sites.
- Monitor quality and release remotely. Seal’s digital systems will record every manufacturing step across the network. The quality personnel at the Catapult, which will be acting as the central hub, will review that data and carry out the review and release of exemplar batches from all sites. Its Qualified Person, the individual legally responsible for certifying that each batch meets required standards, will conduct this review and release process from a single point of control.
- Operate under a single licence. The whole network is designed to be able to be run under one manufacturing licence, in line with the MHRA’s Framework for Point-of-Care and Modular Manufacturing which was published in June 2025.
The result of this proof-of-concept trial will be a blueprint for building decentralized manufacturing networks in the UK and beyond. Similar regulations are being developed/ implemented in the US, China and other large cell therapy markets.
“This grant marks Ori’s ongoing commitment to enabling widespread patient access to life-saving cell and gene therapies. The UK has pioneered this model, but until now it has been unable to implement it. Successful implementation requires standardizing manufacturing through automation, and digitization to enable remote monitoring, quality control and the consistency required by Good Manufacturing Practice (GMP). In this PoC trial, we aim to prove out the distributed manufacturing concept in the UK and set an example for the US, China and other markets that are considering this model. This pioneering effort will improve patient access, shorten vein-to-vein times and help bring treatment closer to the patients who need it.” — Jason C. Foster, CEO, Ori Biotech
Addressing the limitations of centralized manufacturing
Most cell therapies, like CAR-T, are made in a small number of large, specialized facilities. For autologous therapies, which are made from each patient’s own cells, the process of manufacturing, testing, release and return to the patient can take weeks or even months. Transport, logistics and extra steps such as freezing and thawing add time and cost, while limited capacity and complex scheduling restrict how many patients can be treated, and where. A decentralized network approach aims to remove some of these barriers, by improving access and shortening turnaround times, all while maintaining or even reducing costs. This pilot follows the introduction of the MHRA’s Human Medicines Modular Manufacture and Point of Care Regulations 2025, which made the UK the first country to establish a dedicated legal framework for point-of-care manufacturing.
“The UK has pioneered the regulatory thinking that makes decentralized manufacturing possible; the task now is to show how it works in practice. That is what makes this pilot so important. The Cell and Gene Therapy Catapult’s contribution is to demonstrate that the quality and release of advanced therapies can be coordinated from a single point of control, even when those therapies are being manufactured across a network of sites. Demonstrating that robust quality oversight and distributed manufacturing can work together is a crucial step towards giving developers the confidence and flexibility to manufacture these therapies closer to patients. It is exactly the kind of challenge the CGT Catapult exists to help the sector solve.” — Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult
“Bringing cell therapy manufacturing closer to patients requires more than placing equipment in different locations. It means making those sites work as one coordinated network, with consistent processes, clear responsibilities and robust quality oversight. At Adthera Bio, our focus is on making that model work in practice. Working with Ori Biotech and CGT Catapult, this project will allow us to test how local manufacturing and centralized oversight can operate together, building the evidence needed to help developers adopt decentralized approaches with confidence. For commercial therapies, this model can deliver better products and bring them to more patients. Our ambition is to make manufacturing a bridge to treatment, rather than a barrier to access,” said Stuart Curbishley, CTO of Adthera Bio.
About Ori Biotech
Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products’ clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The IRO platform has received FDA Advanced Manufacturing Technology (AMT) designation, recognizing it as a leading next-generation solution for cell and gene therapy manufacturing.
For news and updates, visit oribiotech.com/news-insights.